Alteraciones en la dieta alimentaria de algunos peces comerciales pr efecto del fenómeno El Niño

Estudio de los restos estomacales obtenidos de los cruceros bio-oceanográficos, Eurekas y otras operaciones

Dieta del lobo fino (Arctocephalus australis) y del lobo chusco (Otaria byronia) en la costa sur del Perú en febrero de 1998

Informa sobre la dieta de los lobos finos y chuscos en cuatro localidades de la costa sur del Perú en febrero de 1998, mes en que la distribución y abundancia de los principales recursos marinos fueron severamente afectados por la ocurrencia de El Niño. Establece una relación de las presas consumidas por estos mamíferos marinos bajo condiciones de El Niño, con énfasis en la ocurrencia y tamaños de anchovetas encontradas en su dieta en varios puntos de la costa sur del Perú.

La dieta del guanay Leucocarbo bougainvilli y el piquero peruano Sula variegata en la costa peruana durante agosto de 1997

Presenta los resultados de las evaluaciones llevadas a cabo en agosto de 1997, para conocer la dieta de las principales aves guaneras; y además brinda información que contribuye en el monitoreo de la oferta y distribución de los principales recursos pelágicos del sistema de afloramiento peruano y las alteraciones en la composición de la comunidad marina.

Dieta de las aves guaneras en la costa peruana durante noviembre 1999

Estudia la dieta del guanay, del piquero peruano y el camanay en cinco áreas guaneras a lo largo de la costa peruana, encontrándose que el recurso anchoveta fue la presa predominante en la dieta. La dieta de las aves guaneras muestra una buena disponibilidad de anchoveta en la zona norte y centro, especialmente frente a Pisco, asimismo, las mayores concentraciones de peladilla se registraron frente a Pisco.

MACROPHAGES FROM CROHN'S DISEASE PATIENTS EXHIBIT DEFICIENT REPAIR FUNCTIONS

AbstractBackground: Mucosal healing is becoming a major goal in the treatment of Crohn's disease. It has been previously reported that myeloid cells induce mucosal healing in a mouse model of acute colitis. The aim in this study is to investigate the pro-repair function of myeloid cells in healthy donors (HD) and Crohn's disease patients (CD).Methods: Peripheral blood mononuclear cells (PBMC) from HD and CD patients were isolated from blood samples and tested either directly or after differentiation ex-vivo into macrophages (Μφ). Intestinal macrophages (IMACs) were isolated from the bowel mucosa of patients undergoing intestinal surgical resections. Through an in vitro wound healing assay the repairing ability of these various human myeloid cells and the mechanisms responsible of wound healing were evaluated.Results: PBMC and myeloid CD14+ cells from HD and CD were not able to repair at any tested cell concentration. Μφ from HD and ulcerative colitis (UC) patients were able to induce wound healing and this capacity was partially mediated by Hepatocyte Growth Factor (HGF). Remarkably, CD Μφ were unable to promote wound healing and produced lower levels of HGF as compared to Μφ from HD or UC patients. In particular, Μφ from CD in active phase (ACD) exhibited the weakest repair function, but this defect was rescued if rh- GM-CSF was added during the differentiation of PBMCs. Interestingly, IMACs from HD promoted wound healing and produced HGF.Conclusion: We demonstrated that CD Μφ, unlike HD or UC Μφ, were defective in promoting wound healing, in particular if coming from an ACD. This deficient pro-repair function was related to a lower production of HGF. IMACs from HD colonic mucosa induced wound healing, confirming the results obtained with Μφ. Our results are in keeping with the current theory of CD as an innate immunodeficiency. In this context, Μφ may be responsible for the mucosal repair defects observed in CD patients and for the subsequent chronic activation of the adaptive immune response.

Dieta de la anchoveta Engraulis rigens según intervalos de talla. Crucero BIC Jose Olaya Balandra y BIC Humboldt 9906

Describe la dieta de la anchoveta de acuerdo a intervalos de talla y grados latitudinales, entre el 14 y 26 de junio de 1999. Se han verificado cambios en dicha dieta conforme el individuo crece, reflejándose en la presencia de dos "unidades tróficas", la primera comprende individuos de 4 a 9,9 cm y la otra de 10 a 16,9 cm, con características de zooplantofagia y fitoplanctofagia, respectivamente. Estas mismas unidades, ordenadas latitudinalmente y por distancia a la costa, tuvieron un comportamiento variable, sin seguir un patrón definido. Por consiguiente podemos categorizar a la anchoveta como un oportunista trófico.

Variaciones espaciales en la dieta de la anchoveta a finales de la primavera 1999. Crucero BICs José Olaya Balandra y SNP-2 9911-12

Se analizaron las variaciones espaciales en la dieta de la anchoveta, en 1412 ejemplares de 8 y 18 cm. de longitud.

Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.

BACKGROUND: About 30-50% of patients with Crohn's disease (CD) develop fistulae, implying significant disease burden and complicated clinical management. AIM: To assess appropriate use of therapy for fistulizing CD patients enrolled in the Swiss Inflammatory Bowel Disease Cohort using criteria developed by the European Panel on the Appropriateness of Crohn's disease Therapy. METHODS: Specific questionnaires were used to gather information on disease and its management. We assessed appropriateness of therapy at enrolment for adult CD patients with one or several fistulae. RESULTS: Two hundred and eighty-eight CD patients had fistulizing disease, of which 80% had complex fistulae and 32% currently had active draining fistulae. Mean age (s.d.) at diagnosis was 27 years (11), 51% males. Of the patients, 78% were judged as having globally an appropriate therapy, which was more often given for complex fistulae (87%) than for simple fistulae (67%). Antibiotics, azathioprine/MP, methotrexate and conservative surgery were almost always appropriate. Anti-tumor necrosis factor α was considered globally appropriate (91%), although most often with an uncertain indication. The 5ASA compounds, steroids and aggressive surgery were most often inappropriate (84%, 58% and 86% respectively). CONCLUSIONS: Formal appropriateness criteria for CD therapy were applied to a national cohort of IBD patients. For more than three-quarters of the patients with fistulizing CD, therapy was globally appropriate.

Dieta de la merluza peruana en el verano 2004. Crucero BIC Olaya 0401-02

Se ha analizado la dieta consumida por Merluccius gayi peruanus, durante el verano 2004, en función a la talla, sexo, latitud, estrato de profundidad y grupo horario. Además, se ha determinado la ración diaria, los grupos tróficos, y la variación del peso del contenido estomacal. Se analizaron 4584 estómagos, sólo el 36% presentó contenido; se identificaron 43 tipos de presas: 18 crustáceos, 18 peces y 7 cefalópodos; dominaron los eufáusidos (%IRI = 80,5) y el canibalismo (%IRI = 13,3). No se registró diferencias en la dieta por sexos en individuos menores de 35 cm, pero sí entre los mayores o los menores a esta talla. Las unidades tróficas variaron por estrato de profundidad y latitud.

Relaciones ontogénicas y espacio-temporales en la dieta del calamar gigante (Dosidicus gigas) en Perú, utilizando un Modelo Aditivo Generalizado

El calamar gigante Dosidicus gigas (d'Orbigny, 1835) es un depredador importante en el ecosistema del Perú. Se postula que el papel del calamar gigante varía teniendo en cuenta la talla, tiempo, hora, temperatura y distribución espacial. Para comprobar esta hipótesis se aplicó un modelo aditivo generalizado (GAM) en datos biológicos de alimentación de 4178 calamares gigantes capturados por la flota industrial pesquera a lo largo del litoral peruano (3ºS a 18ºS) desde 2 a 299 millas náuticas (mn) de distancia a la costa desde el año 2004 a 2009 realizados por el Laboratorio de Ecología Trófica del Instituto del Mar del Perú (IMARPE). La talla de los calamares estudiados fluctuó entre 14 y 112 cm de longitud de manto (LM). En total 43 item-presa fueron registrados, los grupos más importantes fueron los cefalópodos (Dosidicus gigas), Teleosteii (Photichthyidae, Myctophidae y Nomeidae) y Malacostraca crustáceos (Euphausiidae). Las presas principales fueron D. gigas (indicando canibalismo) en términos gravimétricos (% W=35.4), los otros cephalopodos en frecuencia de ocurrencia (FO=14.4), y los eufáusidos en términos de abundancia relativa (% N=62.2). Estos resultados reflejan una alta variabilidad de la dieta, y un espectro trófico similar en comparación con otras latitudes en ambos hemisferios (México y Chile). Los modelos GAM muestran que todas las variables predictoras fueron significativas en relación a la variable respuesta llenura estomacal (p <0.0001). La llenura estomacal fue mayor en los individuos juveniles, también durante la noche hubo mayor consumo, mientras no se reflejaron tendencias en la alimentación con relación a la temperatura superficial del mar (TSM), pero espacialmente se observan cambios en la dieta, aumentando el porcentaje de llenura a medida que esta especie se aleja de la costa. Por lo tanto se concluye que la dieta del calamar gigante depende de la talla y su distribución espacio-temporal.

Medical treatments and risk factors for resection surgery in Crohn's disease: results from the Swiss IBD Cohort Study

Background: Surgery has been previously reported to be necessary in up to 80% of Crohn's disease (CD) patients, and up to 65% of patients needed reoperation after 10 years. Prevention of surgery is therefore a particularly important issue for these patients. Treatment options are controversial and data on them are scarce. This study reports medical treatments and main clinical risk factors in CD patients having undergone one or several surgeries. Risks for being free from surgery were also assessed. Methods: Retrospective cohort study, using data from patients included in the Swiss IBD cohort study from November 2006 to July 2011. History of resective surgeries, clinical characteristics and drug regimens were collected through detailed medical records. Univariate and multivariate analyses for clinical and therapeutic factors were performed. Cox regression was made to estimate free-of-surgery risks for different phenotypes and drugs. Results: Out of 1138 CD patients in the cohort, 721 (63.4%) were free of surgery at inclusion; 203 (17.8%) had 1 surgery and 214 (18.8%) >1 surgery. Main risk factors for surgery were disease duration 5-10 years (OR=2.92; p<0.001) and >10 years (OR=10.45; p<0.001), as well as stricturing (OR=8.33; p<0.001) or fistulizing disease (OR=7.34; p<0.001). Risk factors for repeated surgery was disease duration >10 years (OR=2.55; p=0.006) or fistulizing disease (OR=3.79; p<0.001). At inclusion, 107 patients (25.7%) had at least one anti-TNF alpha, 168 (40.3%) at least one immunosuppressive agent, and 41 (9.8%) at least 5-ASA or antibiotics. 64 (15.3%) were not exposed to any medical treatment. Kaplan-Meier curves showed that the risk of being free of surgery was 65% after 10 years, 42% after 20 years and 23% after 40 years. Surgical risks were four resp. five time higher for fistulizing and stricturing phenotypes (Hazard ratio (HR) =4.2; p<0.001; resp. HR=4.7; p<0.001) compared to inflammatory phenotype. Surgical risk was 4 times lower (HR=0.27; p=0.063) in CD patients under anti-TNF alpha compared to those under other or no drugs. Conclusion: The risk of having resective surgery was confirmed to be very high for CD in our cohort. Duration of disease, fistulizing and stricturing disease pattern enhance the risk of surgery. Anti-TNF alpha tends to lower this risk.

Development of the Crohn's disease digestive damage score, the Lémann score.

Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An instrument to measure cumulative structural damage to the bowel, which may predict long-term disability, is needed. The aim of this article is to outline the methods to develop an instrument that can measure cumulative bowel damage. The project is being conducted by the International Program to develop New Indexes in Crohn's disease (IPNIC) group. This instrument, called the Crohn's Disease Digestive Damage Score (the Lémann score), should take into account damage location, severity, extent, progression, and reversibility, as measured by diagnostic imaging modalities and the history of surgical resection. It should not be "diagnostic modality driven": for each lesion and location, a modality appropriate for the anatomic site (for example: computed tomography or magnetic resonance imaging enterography, and colonoscopy) will be used. A total of 24 centers from 15 countries will be involved in a cross-sectional study, which will include up to 240 patients with stratification according to disease location and duration. At least 120 additional patients will be included in the study to validate the score. The Lémann score is expected to be able to portray a patient's disease course on a double-axis graph, with time as the x-axis, bowel damage severity as the y-axis, and the slope of the line connecting data points as a measure of disease progression. This instrument could be used to assess the effect of various medical therapies on the progression of bowel damage. (Inflamm Bowel Dis 2011).

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.

Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.

BACKGROUND: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. AIM: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD. METHODS: We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI of <or=4 and response as a reduction in the HBI of >3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response. RESULTS: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4-6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smoking status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4-6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall. CONCLUSION: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long-term effectiveness.